Evidence map›Paper›PMID 42731887›Full record

ArticleLupus science & medicine2026

Integrated metabolomics and DNA methylation signatures and their association with flare remission in SLE.

Mary Horton, Dylan Johnson, Kirsten E Overdahl, Joanne Nititham, Kimberly E Taylor, Patricia Katz, Jimmie Ye Chun, Jinoos Yazdany, Maria Dall'Era, Lisa F Barcellos and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mary HortonNational Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-0854-4219
Dylan JohnsonIntegrative Bioinformatics Support Group, National Institute of Environmental Health Sciences, Durham, North Carolina, USA.
Kirsten E OverdahlMass Spectrometry Research Center, National Institute of Environmental Health Sciences, Durham, North Carolina, USA.
Joanne NitithamNational Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
Kimberly E TaylorDivision of Rheumatology, University of California San Francisco, San Francisco, California, USA.
Patricia KatzDivision of Rheumatology, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0002-8146-2519
Jimmie Ye ChunDivision of Rheumatology, University of California San Francisco, San Francisco, California, USA.
Jinoos YazdanyDivision of Rheumatology, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0002-3508-4094
Maria Dall'EraDivision of Rheumatology, University of California San Francisco, San Francisco, California, USA.
Lisa F BarcellosDivision of Epidemiology/Biostatistics, School of Public Health, University of California, Berkeley, California, USA.
Jian-Liang LiIntegrative Bioinformatics Support Group, National Institute of Environmental Health Sciences, Durham, North Carolina, USA.
Alan K JarmuschMass Spectrometry Research Center, National Institute of Environmental Health Sciences, Durham, North Carolina, USA.
Lindsey A CriswellNational Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
Cristina M LanataNational Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA cristina.lanata@nih.gov.

Funding

Mass Spectrometry-based Untargeted MetabolomicsZICES103363 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI JARMUSCH, ALAN · 2021 to 2025
$6.5M
Intramural NIH HHS ZIC ES103363NCCDPHP CDC HHS U01 DP005120
6 · The paper itself

Abstract

objectiveIdentify whether changes in metabolite abundance are associated with SLE flare remission and changes in DNA methylation (DNAm).

methods40 multiethnic patients with SLE were recruited during a rheumatologist-confirmed flare and returned to the clinic 3 months later. Per visit, we obtained blood samples and generated untargeted metabolomics (ultra-high performance liquid chromatography coupled to high-resolution mass spectrometry) and DNAm (Illumina EPIC array) profiles. We identified chemical features whose change between visits was associated with remission at the follow-up visit using the

results16 patients with SLE were in remission at the follow-up visit. Remitters and non-remitters had similar demographics and disease activity at baseline. We identified 62 chemical features whose changes over time were associated with remission. 19 were assigned a putative consensus chemical formula. Two were confirmed with reference standards-adenosine (interaction coefficient (β): 2.29, 95% CI 1.44 to 3.14) and bilirubin (β: 2.02, 95% CI 1.09 to 2.94). We identified 23 significantly correlated chemical feature-DNAm pairs (p<0.05/62×291). This included a strong correlation between adenosine and four DNAm sites, including three within immune-related genes

conclusionChanges in chemical features, including confirmed metabolites bilirubin and adenosine, were associated with flare remission and changes in DNAm at SLE-relevant loci. Metabolites and their correlations with DNAm might serve as indicators of immune function and improve our knowledge of determinants of response to treatment. Future studies are needed to confirm the identities of metabolites and robustness of findings.

Indexed as

DNA MethylationLupus Erythematosus, SystemicMetabolomicsAdenosineAdultBilirubinBiomarkersFemaleHumansMaleMiddle AgedRemission InductionSymptom Flare UpAdenosineBilirubinBiomarkersAutoimmune DiseasesAutoimmunityLupus Erythematosus, Systemic

Identifiers

PMID42731887
PMCPMC13583882

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.